K. Bylow

发表

Long Term Outcomes of Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with A Simultaneous Hypofractionated Boost to the Prostate For Very High Risk Adenocarcinoma of the Prostate, a Prospective Phase II Clinical Trial.

W. See, M. Siker, C. Johnstone, 2021, Practical radiation oncology.

The relationship between anxiety about prostate cancer among patients with biochemical cancer recurrence and the use of complementary and alternative medicines, diet, and exercise

S. Mohile, W. Stadler, W. Dale, 2017, Family Medicine and Community Health Journal.

Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.

S. Mohile, W. Stadler, W. Dale, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Older Patients with High-Risk Myelodysplastic Syndromes (MDS): The Emerging Role of Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT)

J. Troy, W. Saber, K. Bylow, 2014, Current Hematologic Malignancy Reports.

The Vulnerable Elders Survey‐13 Predicts Mortality in Older Adults with Later‐Stage Colorectal Cancer Receiving Chemotherapy: A Prospective Pilot Study

S. Mohile, W. Dale, H. Kindler, 2013, Journal of the American Geriatrics Society.

TEMPORAL ARTERITIS: THE IMPORTANCE OF RECOGNIZING SENESCENT CHANGES VERSUS QUIESCENT DISEASE IN A TEMPORAL ARTERY BIOPSY

D. Brauner, K. Bylow, 2006, Journal of the American Geriatrics Society.

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

David C. Smith, M. Kohli, D. Petrylak, 2014, Cancer.

The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?

Scott C. Johnson, E. Messing, E. Guancial, 2020, Clinical genitourinary cancer.

Immune Check Point Inhibition in Sarcomatoid Renal Cell Carcinoma: A New Treatment Paradigm

K. Iczkowski, M. Riese, D. Kilari, 2017, Clinical genitourinary cancer.

Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid

C. Ryan, D. Huo, W. Stadler, 2007, BJU international.

Management of complications of androgen deprivation therapy in the older man.

S. Mohile, W. Dale, K. Mustian, 2009, Critical reviews in oncology/hematology.

677P A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis

E. Messing, S. Mohile, C. Fung, 2020 .

Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer.

Michael R Meager, S. Mohile, W. Stadler, 2010, Critical reviews in oncology/hematology.

Does androgen‐deprivation therapy accelerate the development of frailty in older men with prostate cancer?

S. Mohile, W. Stadler, W. Dale, 2007, Cancer.

Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC).

David C. Smith, A. Belldegrun, M. Kohli, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Falls and physical performance deficits in older patients with prostate cancer undergoing androgen deprivation therapy.

S. Mohile, W. Stadler, M. Lachs, 2008, Urology.

A pilot study of the vulnerable elders survey‐13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation

J. Dignam, S. Mohile, D. Petrylak, 2007, Cancer.

Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.

M. Atkins, E. Posadas, W. Stadler, 2009, Clinical genitourinary cancer.

Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study.

S. Mohile, W. Stadler, W. Dale, 2011, Urology.

A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis.

E. Vokes, H. Hochster, H. Kindler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes With Liver-Directed Therapy for Genitourinary Malignancies: Single-Institution Experience.

D. Kilari, W. Rilling, K. Bylow, 2020, Clinical genitourinary cancer.

801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)

M. Milowsky, C. Fung, D. Kilari, 2020 .

Pancreatic cancer: An update

H. Kindler, K. Bylow, 2007, Current oncology reports.

Management of complications of androgen deprivation therapy in the older man.

S. Mohile, W. Dale, K. Mustian, 2009, Critical reviews in oncology/hematology.

Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).

G. Sonpavde, M. Galsky, N. Hahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.